1. Home
  2. PLSE vs AGIO Comparison

PLSE vs AGIO Comparison

Compare PLSE & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pulse Biosciences Inc (DE)

PLSE

Pulse Biosciences Inc (DE)

HOLD

Current Price

$24.97

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.94

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSE
AGIO
Founded
2014
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2015
2013

Fundamental Metrics

Financial Performance
Metric
PLSE
AGIO
Price
$24.97
$28.94
Analyst Decision
Buy
Buy
Analyst Count
1
8
Target Price
$22.00
$38.88
AVG Volume (30 Days)
338.3K
719.4K
Earning Date
05-07-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
$840.00
$76.75
Revenue Next Year
$287.54
$170.73
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.56
$22.24
52 Week High
$28.53
$46.00

Technical Indicators

Market Signals
Indicator
PLSE
AGIO
Relative Strength Index (RSI) 52.72 51.85
Support Level $23.60 $26.71
Resistance Level $26.30 $29.64
Average True Range (ATR) 1.53 1.38
MACD -0.12 0.04
Stochastic Oscillator 26.98 56.48

Price Performance

Historical Comparison
PLSE
AGIO

About PLSE Pulse Biosciences Inc (DE)

Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: